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Abstract
Introduction A small proportion of patients with acute intermittent porphyria (AIP) suffer from recurrent porphyric
attacks, with a severely diminished quality of life. In this retrospective case-control study, the burden of disease is
quantified and compared among three AIP patient subgroups: cases with recurrent attacks, cases with one or
occasional attacks and asymptomatic carriers.
Methods Data from patient records and questionnaires were collected in patients between 1960 and 2016 at the ErasmusMedical
Center, Rotterdam, the Netherlands. We collected symptoms related to porphyria, porphyria related complications, attack fre-
quency, hospitalisation frequency, hospitalisation days related to acute porphyric attacks, frequency of heme infusions and
medical healthcare costs based on hospitalisations and heme therapy.
Results In total 11 recurrent AIP cases, 24 symptomatic AIP cases and 53 AIP carriers as controls were included. All
recurrent patients reported porphyria related symptoms, such as pain, neurological and/or psychiatric disorders, and
nearly all developed complications, such as hypertension and chronic kidney disease. In the recurrent cases group,
the median lifelong number of hospitalisation days related to porphyric attacks was 82 days per patient (range 10–
374), and they spent a median of 346 days (range 34–945) at a day-care facility for prophylactic heme therapy; total
follow-up time was 243 person-years (PYRS). In the symptomatic non-recurrent group the median lifelong number
of hospitalisation days related to porphyric attacks was 7 days per patient (range 1–78), total follow-up time was
528 PYRS. The calculated total medical healthcare cost for recurrent cases group was €5.8 million versus €0.3
million for the symptomatic cases group.
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Introduction
Acute intermittent porphyria (AIP) is a rare inherited metabol-
ic disorder in which patients suffer from acute porphyric
attacks with abdominal pain, often with anxiety, nausea,
tachycardia and hypertension. During severe attacks,
psychiatric symptoms, hyponatremia, seizures and pro-
gressive peripheral neuropathy can occur (Bylesjö et al
2009). Such attacks can progress to paralysis, respiratory fail-
ure, and death if patients are not treated. Apart from acute
porphyric attacks, patients have a long term increased inci-
dence of hypertension, kidney disease and hepatocellular car-
cinoma (HCC) (Andersson et al 1996; Andersson et al 2000;
Sardh et al 2013).
AIP is caused by mutations in the hydroxymethylbilane
synthase (HMBS, OMIM 609806) gene. In literature it has
been described that less than 10% of HMBS gene mutation
carriers experience acute porphyric attacks during their lives
(Puy et al 2010). However, a recent study indicates an even
lower clinical penetrance of about 1% (Chen et al 2016). Ever
since heme became the treatment of choice in the 1980s, por-
phyria attacks have been treated with intravenous heme.
This has been shown to be effective in improving both
the biochemical abnormalities, clinical symptoms and
preventing deterioration of the neurological defects. It
is therefore regarded as a life-saving therapy (Whatley and
Badminton 2013).
Only a small subset of the symptomatic patient group
suffers from recurring porphyric attacks several times
per year. Recurring attacks are treated with weekly pro-
phylactic heme infusions (Marsden et al 2015). This
therapy is, however, complicated by iron overload, phle-
bitis, venous thrombosis and frequent need for venous
access devices, and is a significant burden for the pa-
tient (Willandt et al 2016). Patients who suffer from
recurrent attacks report a low quality of life (QoL)
and a negative impact on several aspects of everyday
life, including unemployment, personal relationships and
long-term disability (Millward et al 2001; Jiménez-Monreal
et al 2015; Naik et al 2016).
New in this study is the analysis of the recurrent
patients separate from sporadically symptomatic cases,
and HMBS gene carriers as controls. Although recurring
porphyric attacks have been shown to be associated
with a poor quality of life, the financial and personal
burden of this disease in relation to the occurrence and
frequency of attacks are unclear. Therefore, in order to
get a better insight into the burden of AIP, we studied
the prevalence of porphyria symptoms and complica-
tions, in addition to the costs related to recurrent
porphyric attacks and compared them to symptomatic
porphyria cases and asymptomatic gene carriers in a case-
control study design.
Methods
Data collection
In this single-centre retrospective longitudinal observational
cohort study, all patients with AIP attending the clinic of the
Porphyria Center in the Erasmus Medical Center (Rotterdam,
the Netherlands) between 1960 and 2016 were included. The
diagnosis AIP was based on either a known HMBS gene mu-
tation, or on positive biochemistry (defined as a delta-
aminolaevulinic acid (ALA) and porphobilinogen (PBG) level
at least four times the upper limit of normal) in combination
with a decreased porphobilinogen deaminase (PBGd) enzyme
activity measured in either erythrocytes or lymphocytes.
Data were collected by R.A.N. and J.G.L. from patients’
electronic and paper records, and from self-reported question-
naires (Suppl. file 1). The patient charts and file data were first
reviewed.When the retrospective data was unclear (e.g. due to
old, poorly hand-written notes), a consensus was formed
which was entered in the final database, or the data was
discarded.
AIP patients with a proven diagnosis were eligible for in-
clusion. A confirmed acute porphyric attack was defined as an
episode of abdominal pain in parallel with a significant rise in
urinary ALA and PBG levels (≥ 4 times upper limit of normal)
which necessitated a verified visit or admission to a hospital
for diagnosis and treatment. Hospitalisations were defined as
hospitalisations with a confirmed acute porphyric attack.
We collected data on (1) porphyria symptoms and long-
term complications, (2) employment status, (3) hospitalisation
episodes, hospitalisation days, amount and frequency of heme
infusions (heme arginate, Normosang®, Orphan Europe), (4)
heme dosage schedules, duration of prophylactic heme thera-
py, complications of heme therapy, placement of a Port-A-
Cath® (PAC, Smiths Medical), oral contraception use, thera-
py with GnRH analogues, analgesia dependence and the age
and cause of death. The annualised attack rate was defined as
the number of attacks in all observed years of follow up,
counting the number of confirmed acute porphyric attacks
and dividing by the number of follow up years.
The medical ethics committee of the Erasmus Medical
Center, Rotterdam, the Netherlands, approved prospective
and retrospective data collection for this study (MEC 2014–
593). Patients were asked to sign informed consent during
visits to the outpatient clinic. Also, they have approved the
use of anonymous retrospective medical data without in-
formed consent.
Patient subgroup definitions
AIP patients were classified in three subgroups based on phe-
notypic characteristics. The first subgroup comprised cases
with recurrent attacks, defined as patients who have more than
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four attacks in any year, or are on prophylactic heme therapy.
The second subgroup was comprised of symptomatic cases,
defined as patients who have experienced at least one con-
firmed acute porphyric attack, but who did not meet the def-
inition of recurrent attack cases. The third subgroup com-
prised asymptomatic controls, defined as persons who carry
a HMBS gene mutation but have never experienced a proven
acute porphyric attack.
Cost of care analysis
To calculate the costs of care, we examined paper or electronic
hospital records to count the number of verifiable heme infu-
sions and hospitalisations (for day care and regular admission)
for each individual. The approach was to be as conservative as
possible, all data needed to be verifiable in the charts. Total
basic-costs were calculated per individual including only
hospitalisations, use of day-care facilities and heme arginate
ampoules; the costs are presented per group. Prices are calcu-
lated based on 2016 data, historical prices or inflation were not
taken into account. These basic costs of care are therefore
limited to costs of hospital care and medication and do not
take other indirect costs to the patient or society into account.
Statistical analysis
Statistical analyses were performed with IBM SPSS Statistics
for Windows (version 21.0. Armonk, NY: IBM Corp.).
Parameters were tested for normality using the Shapiro-Wilk
test for normality. Normally distributed numerical data were
compared among groups with one-way ANOVA, Bonferroni
corrected. Non-parametric numerical independent data were
analysed with Kruskal-Wallis’ test. Categorical data were
analysed using the linear-by-linear Chi-square association-
test, or Fischer’s exact test.
Supplementary methods description
Assays for porphyrins, porphyrin precursors and enzyme ac-
tivity measurements were analysed as previously described
(de Rooij et al 2003), see Suppl. file 2.
Results
Cohort description
The study cohort consisted of 88 individuals with AIP from 49
families, baseline characteristics are presented in Table 1. In
77 patients the diagnosis of AIP was confirmed by identifying
a HMBS mutation. Twenty-five different HMBS gene muta-
tions were identified (Suppl. file 3), the R116W (c.346C>T)
mutation was the most common mutation (21 subjects, 24%).
In the remaining 11 individuals the diagnosis AIP was based
on biochemical test results in combination with decreased
HMBS enzyme activity.
Eleven patients (13%) were categorised as recurrent cases
(subgroup R), 24 (27%) patients were categorised as symp-
tomatic cases (subgroup S) and 53 persons (60%) were
categorised as asymptomatic AIP carriers (subgroup A, con-
trol group). The male-to-female ratio, BMI and age at diagno-
sis were similar in all three groups. The age of onset of symp-
toms was not different between both symptomatic groups.
Laboratory results are presented in Fig. 1 and details are pre-
sented in Suppl. file 4.
Prevalence of porphyric symptoms
Life-long prevalence of acute porphyria-related symptoms,
long-term complications and other parameters such as unem-
ployment in all three groups are presented in Table 2. Patients in
the recurrent cases group report more porphyria related symp-
toms: pain, neurological deficits, and psychiatric symptoms.
These differences were statistically significantly (p-values
<0.001), except for the psychiatric symptoms. The differences
between reported symptoms from patients in both symptomatic
groups are smaller and mostly not statistically significantly dif-
ferent. However, the prevalence of several symptoms is at least
double in the recurrent cases group compared to the symptom-
atic group, Suppl. file 5; malaise (p = 0.01, 82% of patients in
recurrent group versus 29% in symptomatic group), fatigue
(p < 0.01, 91 vs 38%), nausea (p < 0.01, 100 vs 46%), anxiety
(p < 0.01, 46 vs 21%), psychosis/hallucinations (p = 0.03, 36 vs
4%) and seizures (p < 0.05, 46 vs 13%).
Prevalence of long-term complications
Hypertension was more prevalent in the recurrent cases group
(73%) and in the symptomatic cases (71%) compared to the
asymptomatic control group (26%). Kidney disease was also
more prevalent in the recurrent cases (64%) and symptomatic
cases (46%) compared to asymptomatic controls (13%),
Table 2 and details in Suppl. file 5. There were four cases with
hepatocellular carcinoma (HCC); one from the recurrent cases,
two from the symptomatic cases, and one from the asymptom-
atic controls. One of the HCC patients was still alive at the time
of database lock. In three patients, the tumour was inoperable
and/or there were metastases at presentation. The fourth patient
unfortunately died due to surgical complication, although the
tumour was detected as an incidental finding in a curative stage.
Anemia was present in 14 cases, and mostly prevalent in
the recurrent cases (7/11, 64%) and symptomatic cases (4/24,
17%) compared to asymptomatic controls (3/53, 6%). Kidney
disease was present in 79% of the anemia cases (11/14).
Anemia without renal insufficiency was present in 21% of
all anaemic persons (3/14).
J Inherit Metab Dis
Number of hospitalisations, day-care-admissions,
heme therapy and attack frequency
The life-long hospital admissions, duration and the calculated
costs are presented in Table 3. Individuals from the recurrent
group were hospitalised for a median of 82 days and received a
median of 399 total ampoules of heme per person. Heme sched-
ules differed among patients and over time, ranging from every
other week, to weekly and biweekly. Individuals from the symp-
tomatic group were hospitalised for a median of 7 days for acute
attacks and received amedian of 3 ampoules of heme per person.
The median total cost per person of combined heme/albumin
infusions for the recurrent subgroup was € 292.000 versus
€2.200 for the symptomatic subgroup. The costs for the recurrent
patient group accounted for at least 95% of the total costs.
We calculated the number of attacks for the symptomatic
and recurrent groups, per year of total follow-up. In total, in
the recurrent group there were 137 acute attacks in 407 years
of follow-up, or 0.3366 attacks per year. In the symptomatic
group, there were 56 acute attacks in 959 years of follow-up,
or 0.0584 attacks per year. The patients in the recurrent group
suffered 5.8 times more attacks during follow-up. Figure 2
illustrates the follow-up time, the attacks and heme therapy
for each patient in the symptomatic and recurrent groups over
the observation period.
Comparing the number of attacks before the start of heme
prophylaxis to the number of attacks during heme prophylax-
is, a 50% reduction in number of attacks was observed; before
heme prophylaxis there were 2.28 attacks per year, during
heme prophylaxis 1.11 attacks per year.
Table 1 Baseline characteristics
of acute intermittent porphyria
cohort, categorised in three
groups based on symptoms
Recurrent
cases (n = 11)
Symptomatic
cases (n = 24)
Asymptomatic
controls (n = 53)
All (n = 88)
Attacks – lifelong (n) 8 (2–54) 2 (1–7) 0
Sex (% female) 63.6 75.0 66.0 68.2
BMI a (kg/m2) (mean ± SD) 24.9 ± 6.2 25.1 ± 8.1 25.2 ± 4.4 25.1 ± 5.8
Age at diagnosis (years) 31 (14–55) 30 (2–52) 32 (5–72) 31 (2–72)
Age of onset (years) 36 (16–56) 30 (18–55) – 30 (16–56)
Smoking (n, % ever smoker) 6, 55 11, 46 18, 34 35, 40
HMBS gene mutations (n) 5 16 18 25
No. of families within group (n) 11 20 33 49
Follow-up duration (PYRS) 21 (3–38) 22.5 (0–53) 8 (1–45) 13 (0–53)
Data are presented with median (range), unless otherwise specified. There was no statistical difference between
groups for sex, BMI, age of diagnosis and age of onset
Attack numbers were based on life-long verified acute porphyric attacks requiring hospitalisation. Subgroups
were based on phenotypic characteristics: recurrent cases were defined as having more than four attacks in any
year, or on prophylactic heme therapy; symptomatic cases were defined as having experienced one or more
confirmed acute porphyric attack; asymptomatic controls never experienced a proven acute porphyric attack.
Data on smoking are presented as life-long prevalence
BMI, body mass index; HMBS, hydroxymethylbilane synthase; PYRS, person-years
a first available BMI after age ≥ 18 years
Fig. 1 The distribution of first measured urinary porphyrin precursors in
the different AIP groups. Subgroups were based on phenotypic
characteristics: recurrent cases were defined as having more than four
attacks in any year, or on prophylactic heme therapy; symptomatic
cases, were defined as having experienced one or more confirmed acute
porphyric attack; asymptomatic controls never experienced a proven
acute porphyric attack. Abbreviations: A, asymptomatic controls; ALA,
delta-aminolevulinic acid; PBG; porphobilinogen; R, recurrent cases; S,
symptomatic cases. The grey areas mark increased levels, starting at 4
times the upper limit of normal (ULN) 4xULN ALA ≥ 184 μmol/L 4x
ULN PBG ≥ 36 μmol/L
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Table 2 Prevalence in
percentages (%) of life long
porphyria-related symptoms and
complications in subgroups of the
acute intermittent porphyria
cohort
Recurrent
cases (n = 11)
Symptomatic
cases (n = 24)
Asymptomatic
controls (n = 53)
Linear-by-linear
Chi2-association test
Acute symptomsa 100 83.8 35.8 p < 0.001
Pain 100 91.7 30.2 p < 0.001
Neurological symptoms 81.8 45.8 17.3 p < 0.001
Psychiatric symptoms 81.8 33.3 18.9 p < 0.001
Long-term complications
Hypertension 72.7 70.8 26.4 p < 0.001
Chronic kidney disease 63.6 45.8 13.2 p < 0.001
Hepatocellular carcinoma 9.1 8.3 1.9 p = 0.15
Other parameters
Anemia 63.6 16.7 5.7 p < 0.001
Seizures 45.5 12.5 0 p < 0.001
Dependence on analgesics 63.6 0 3.7 p < 0.001
Unemployment 63.6 33.3 20.8 p = 0.021
Data are presented as the percentage (%) of patients or persons scoring positive on one of the symptoms in the
categories during their life. Subgroups were based on phenotypic characteristics: recurrent cases were defined as
having more than four attacks in any year, or on prophylactic heme therapy; symptomatic cases were defined as
having experienced one or more confirmed acute porphyric attack; asymptomatic controls never experienced a
proven acute porphyric attack. Data on unemployment rate are presented as life-long prevalence.
Statistical differences between groups was tested with linear-by-linear Chi-squared association test,
p-values are presented
In Suppl. file 5, all scored symptoms and p-values are presented
a Acute symptoms are: malaise, fatigue, nausea, vomiting, diarrhoea, constipation and red urine
Table 3 Hospitalisations, day-
care admissions and costs related
to proven acute porphyric attacks
in presented acute intermittent
porphyria cohort
Recurrent cases (n = 11) Symptomatic cases (n = 24)
Hospitalisations days (n) 82 (10–374) 7 (1–78)
Day-care treatment (n) 346 (34–945) 0
Heme arginate therapy (n) 399 (79–945) 3 (0–24)
Hospitalisation costs (in k euros) 41 (5–193) 3.5 (0.4–39)
Day-care costs (in k euros) 149 (15–406) 0
Heme arginate costs (in k euros) 292 (58–692) 2.2 (0–17.5)
Follow-up time (years) 21 (3–38) 22.5 (0–53)
Total group cost (in k euros) 5843 288
Total follow-up time (PYRS) 243 528
Cost per person year (in k euros) 24 (3–63) 0.5 (0a – 31)
All data are presented as: median (range), and data are given per person per group over total observation period,
except for total group cost and total follow-up time in PYRS. The presented costs are an estimation, see manu-
script for more details
Subgroups are based on phenotypic characteristics: recurrent cases are defined as having more than four attacks in
any year, or on prophylactic heme therapy; symptomatic cases are defined as patients who have experienced at
least one confirmed acute porphyric attack
Costs were calculated using prices based on 2016 for hospital stay and heme arginate.
k, 1000; PYRS, person-years
a One patient did have an acute porphyric attack, however, data on details were missing, and costs could not be
calculated and are thus presented as zero, this patient was the index patient in the family
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Description of cases with premature death
At the end of the observation period (31 December 2016) the
median age of the AIP cohort was 54 years (range 18–81).
Five patients died during the observation period, median age
of death was 65 years (range 34–72 years). All deaths were
directly or indirectly related to porphyria. Four out of five
patients were in the recurrent attack group. One person died
in the symptomatic case group, this was a male patient pre-
senting at age 41 years with a first uncomplicated porphyric
attack. At age 72 years, HCC was diagnosed following an
incidental finding on a PET CT-scan performed for headache.
He underwent hemi-hepatectomy but died from a brainstem
hemorrhage, 13 days post-operatively. A detailed description
of all deceased cases is presented in Suppl. file 6.
Recurrent cases subgroup
The details of the recurrent cases subgroup are presented in
Table 4. Four out of 11 patients (36%) were male. The median
number of attacks requiring hospitalisation was eight per pa-
tient (range 2–54) following a median observation time of
21 years (range 3–38). The total number of hospitalisation days
per patient ranged between 10 to 374 days. Analgesic depen-
dency was a problem in nearly all recurrent patients (82%,
9/11). Prophylactic heme therapy was initiated in a patient fol-
lowing only two attacks, this was deemed necessary following
progression of neurological symptoms and a progressive rise in
ALA and PBG levels following the first two attacks.
Prophylactic heme schedules were every other week,
weekly, or biweekly, with a duration ranging from 1 to
Fig. 2 Schematic information with individual life lines with porphyric
attacks of all symptomatic cases, including information regarding
prophylactic heme therapy. Subgroups were based on phenotypic
characteristics: recurrent cases were defined as having more than four
attacks in any year, or on prophylactic heme therapy; symptomatic
cases, were defined as having experienced one or more confirmed acute
porphyric attack; asymptomatic controls never experienced a proven
acute porphyric attack. On the left there are 11 lines derived from
patients with recurrent attacks, and on the right 24 lines derived from
symptomatic cases. Each line starts at 15 years of age and ends at the
end of the observation period or death. Each segment on the line
represents one year. The red blocks represent one attack during that
year. The green bars under the timelines represent years in which
patients received prophylactic heme. A cross represents death.
Abbreviations. LTF, lost to follow-up; HCC, hepatocellular carcinoma;
LTx, liver transplant. *not included in study analysis
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14 years. PAC venous access catheters were required in 73%
(8/11) of the cases to secure venous access. However, venous
access was never an absolute limitation for heme therapy. The
total number of heme infusions ranged from 79 to 945 per
patient, while total lifelong medication costs ranged from
€51.500 to €616.046 per patient. Reported side effects of
heme therapy were increased serum ferritin levels and possi-
bly iron overload (9/11, 82%) and phlebitis (4/11, 36%); iron
overload was treated by phlebotomies.
Eleven patients on prophylactic heme therapy have made
attempts to be weaned off heme therapy. This has triggered
acute porphyric attacks in nine patients. One patient was
weaned off heme by slowly reducing the amount of heme over
a period of a year, this was followed by a liver transplantation
(Willandt et al 2016), the only liver transplantation in this
cohort.
Two patients were treated with hormonal interventions.
One was treated with a GnRH-analogue (Syranel®, Pfizer
Inc.) for a limited number of months, since she developed
burdensome postmenopausal symptoms and no effect on re-
ducing attacks. A second patient endured four porphyric at-
tacks within 6 months, but following placement of a hormonal
IUD, she has been free from attacks for 2 years now (52 mg
levonorgestrel-releasing intrauterine device (IUD), Mirena®,
Bayer HealthCare).
Discussion
This study is based on a longitudinal patient cohort and aims
to quantify the severity of disease in AIP patients with recur-
rent attacks and compares this group to patients with sporadic
symptoms and asymptomatic carriers. Patients with recurrent
AIP have a high mortality rate and severe morbidity. Severe
physical and psychological symptoms, including temporary or
permanent disability, lead to unemployment in two-thirds of
the recurrent patients. Hypertension and kidney disease were
observed in respectively 73 and 64% of patients with recurrent
AIP disease. Frequent hospitalisations for acute porphyric at-
tacks, and frequent hospital visits when on prophylactic heme
therapy alone, have a major impact on their lives and contrib-
ute most to the total calculated medical costs.
Studies that focus specifically on the recurrent patient
group are scarce and mainly focus on the group’s diminished
quality of life and therapeutic interventions in patient series
(Marsden et al 2015; Schulenburg-Brand et al 2017). A recent
qualitative study focused on the recurrent patient group (Naik
et al 2016). They investigated the patients’ disease experience
and concluded recurring patients have a markedly impaired
QoL and often turn to alternative medicine. Another study
interviewed five recurrent attack patients and showed that all
of them reported psychological and coping issues with regard
Table 4 Overview of hospitalizations, treatment, and calculated costs in the recurrent AIP patients group
Case 1 2 3 4 5 6 7 8 9 10 11
Sex F F M F M F M M F F F
Age of first attack (years) 16 22 22 38 35 36 56 36 37 39 30
Deceased
(age in years)
42 71 65 34
Cause of deatha Severe attack – respiratory failure HCC Unknownb Euthanasiab
Hospitalizations (n) 54 16 11 11 11 8 7 8 6 4 2
Hospitalizations (in days) 374 185 367 248 60 40 37 33 102 20 10
Heme (ampoules) 508 95 945 890 613 168 102 90 571 399 79
Total medical costs
(in 1k euros )
331.2 61.9 616.0 580.2 399.6 109.5 66.5 58.7 372.2 260.1 51.5
Observation time (months)c 204 36 245 420 48 432 159 456 404 252 420
Total time on prophylactic
heme (months)c
86 14 126 171 152 71 20 14 51 27 16
PACs/AV-shunts (n) 3-4 0 3 5 2 2 0 2 4 1 0
Last measured serum ferritin
(normal 10 – 140 ug/L)
1470 390 3397 1523 1075 1904 NA 37 14 638 NA
The reported hospitalizations were all for confirmed acute porphyric attacks, confirmation was given by a raise in urinary ALA&PBG at the time of
presentation with abdominal pain. Presented medical costs are based on prices in 2016.
Used abbreviations. 1k, 1000; ALA, delta-aminolevulinic acid; AV-shunt, arteriovenous-shunt; F, female M, male; HCC, hepatocellular carcinoma; NA,
not available PAC, port-a-cath;
a for details see supplementary file 5
bNot related to a porphyric attack
c until 31/12/2016 or per date of death
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to the dysfunction the recurrent attack state causes (Wikberg
et al 2000). The preliminary results of the prospective
‘EXPLORE’ study (Congress abstracts: https://icpp2017.org/
wp-content/uploads/2017/06/OCs.pdf) show a high burden of
disease in patients with frequent attacks. Our findings are in
line with these findings, and illustrate one of the effects of the
poor QoL in the high level of unemployment in the recurrent
group. The present study shows there is a large difference in
hospitalisation frequency and subsequent medical costs
between recurrent and sporadic symptomatic patients.
The increased burden, together with the costs, underline
the importance to differentiate among recurrent cases,
symptomatic cases and asymptomatic HMBS gene carriers.
Asymptomatic HMBS gene carriers are without obvious
disease burden or related medical costs, and will require
separate studies to detect any long-term effects of the
mutation.
Major strengths of this study are the prospectively defined
clear study endpoints and categorisation of patients based on
strict criteria for acute porphyric attacks to make comparisons
among the different AIP patient groups possible. However, by
using these strict criteria, an underestimation of the true im-
pact on patient’s life and costs is likely, which may be
regarded as a limitation. Furthermore, a retrospective study
design, with data collection in historical, hand-written, medi-
cal charts and hospital records, will have resulted in missing
data, and again in an underestimation of the burden and
healthcare costs. Since 2014, we have collected data prospec-
tively with questionnaires which can lead to recollection bias
in all patient groups. There is also a definite underrepresenta-
tion of asymptomatic HMBS carriers in this cohort; based on
the number of AIP families. Females were overrepresented in
the present cohort (68%). This overrepresentation was expect-
ed in the symptomatic groups, since females have an increased
risk of attacks (Bonkovsky et al 2014). However, this cannot
explain the overrepresentation in the asymptomatic group
which might be caused by selection bias, since women often
have other reasons for abdominal pain.
There is a high prevalence of long term complications, such
as hypertension, chronic kidney disease and hepatocellular
carcinoma in AIP. In the present study, an increased preva-
lence of hypertension and chronic kidney disease in the recur-
rent patient group was present, compared to the other groups.
Factors contributing to the occurrence of complications have
not yet been elucidated. Long-term exposure to elevated plas-
ma levels of ALA and PBG has been postulated to play a role.
However, we’ve found a marked overlap in ALA and PBG
levels among the recurrent, the symptomatic cases and asymp-
tomatic HMBS gene carriers. There is no good explanation
why some patients with markedly increased levels are without
symptoms or long-term complications. Such subjects are often
referred to as Basymptomatic high excreters^. In this group,
plasma ALA PBG are often as high or even higher than those
found in symptomatic patients (data not shown). For future
studies this could be an interesting group to examine. Other
mechanisms may play a role in AIP-associated tissue damage,
such as human peptide transporter 2 (hPEPT2) genotypes, that
are associated with AIP-associated kidney damage
(Tchernitchko et al 2016). Hypertension was not associated
with renal function decline in AIP patients (Pallet et al 2015).
Figure 2 illustrates the effect of prophylactic heme therapy
on attack rates in the individual patients. This therapy is not
only expensive, but also time-consuming for the patients, and
not fully successful in most patients. However, interrupting
their schedules triggered severe acute porphyric attacks in
nearly all patients. These rebound attacks are probably in part
due to prolonged induction of hepatic heme oxygenase by
administration of exogenous heme, resulting in increased
heme turnover (Doberer et al 2010; Thomas et al 2016).
Interestingly, it has been recently shown that the prevalence
of patients with recurring attacks has increased since the in-
troduction of heme arginate therapy (Schmitt et al 2018). An
explaination could be that the prevalence of patients with re-
curring attacks has increased since the introduction of heme
arginate therapy. There are promising emerging therapies for
AIP such as gene-therapy, short interfering RNA (Chan et al
2015; Fontanellas et al 2016), which are undergoing clinical
trials; until these therapies become available, heme will re-
main the most effective therapy. Consensus definitions of
acute porphyric attacks and acute porphyric symptoms should
be developed, in order to define indications for initiation and
schedules, in patient with frequent and/or disabling porphyric
attacks.
Conclusion and recommendations
In conclusion, AIP patients with recurrent attacks have a high
mortality and morbidity, compared to other symptomatic AIP
patients and to asymptomatic carriers. Recurrent attacks result
in high medical costs and high unemployment rates. In future
studies, these different AIP groups should therefore be
analysed separately, as our study clearly demonstrated that
patients with recurrent attacks are different than sporadical
symptomatic patients and asymptomatic HMBS gene carriers.
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